SG11201909552VA - Combination therapy for prostate cancer - Google Patents

Combination therapy for prostate cancer

Info

Publication number
SG11201909552VA
SG11201909552VA SG11201909552VA SG11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA SG 11201909552V A SG11201909552V A SG 11201909552VA
Authority
SG
Singapore
Prior art keywords
international
johnson
effective amount
therapeutically effective
prostate cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Margaret K Yu
Linda Anne Snyder
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62067858&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201909552V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of SG11201909552VA publication Critical patent/SG11201909552VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
SG11201909552V 2017-04-13 2018-04-09 Combination therapy for prostate cancer SG11201909552VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762485164P 2017-04-13 2017-04-13
PCT/US2018/026661 WO2018191141A1 (fr) 2017-04-13 2018-04-09 Polythérapie contre le cancer de la prostate

Publications (1)

Publication Number Publication Date
SG11201909552VA true SG11201909552VA (en) 2019-11-28

Family

ID=62067858

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909552V SG11201909552VA (en) 2017-04-13 2018-04-09 Combination therapy for prostate cancer

Country Status (33)

Country Link
US (4) US20180296574A1 (fr)
EP (3) EP4176878A1 (fr)
JP (3) JP7141408B2 (fr)
KR (1) KR20190134718A (fr)
CN (2) CN110753545A (fr)
AU (2) AU2018251594A1 (fr)
CA (1) CA3059562A1 (fr)
CL (1) CL2019002871A1 (fr)
CO (1) CO2019011591A2 (fr)
CR (1) CR20190467A (fr)
DK (1) DK3609497T3 (fr)
DO (1) DOP2019000264A (fr)
EA (1) EA201992430A1 (fr)
ES (1) ES2931052T3 (fr)
HR (1) HRP20221327T1 (fr)
HU (1) HUE060460T2 (fr)
IL (2) IL320452A (fr)
JO (2) JOP20190244B1 (fr)
LT (1) LT3609497T (fr)
MA (1) MA48728B1 (fr)
MD (1) MD3609497T2 (fr)
MX (2) MX2019012296A (fr)
MY (1) MY209010A (fr)
NI (1) NI201900105A (fr)
PE (1) PE20200444A1 (fr)
PH (1) PH12019502317A1 (fr)
PL (1) PL3609497T3 (fr)
PT (1) PT3609497T (fr)
RS (1) RS63832B1 (fr)
SG (1) SG11201909552VA (fr)
SM (1) SMT202200467T1 (fr)
UA (1) UA129514C2 (fr)
WO (1) WO2018191141A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001398A2 (pt) 2016-07-29 2019-05-07 Janssen Pharmaceutica Nv métodos para tratamento de câncer de próstata
WO2020139339A1 (fr) * 2018-12-27 2020-07-02 Constellation Pharmaceuticals, Inc. Inhibiteurs de la signalisation de l'ezh2 et du récepteur des androgènes en tant qu'outils pour le ciblage du cancer de la prostate
CN110538150A (zh) 2019-09-26 2019-12-06 湖南瑞林医药科技有限公司 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
JP7442328B2 (ja) * 2020-02-03 2024-03-04 株式会社三共 遊技機
CN113546037B (zh) * 2020-04-20 2024-12-27 鲁南制药集团股份有限公司 一种醋酸阿比特龙栓剂及其制备方法
UY39201A (es) * 2020-05-08 2021-11-30 Janssen Pharmaceutica Nv Tratamientos del cáncer de próstata con combinaciones de acetato de abiraterona y niraparib
BR112023018906A2 (pt) * 2021-03-24 2023-10-10 Astellas Pharma Inc Combinação de talazoparib e um antiandrógeno para o tratamento de câncer de próstata metastático sensível à castração com mutação no gene ddr
CN114306236B (zh) * 2021-12-15 2022-10-21 湖南慧泽生物医药科技有限公司 用于负载醋酸阿比特龙的自微乳体系及组合物和应用
JP7320903B2 (ja) 2021-12-15 2023-08-04 湖南慧▲澤▼生物医▲薬▼科技有限公司 アビラテロン酢酸エステルを含む組成物及び使用
WO2023194525A1 (fr) * 2022-04-07 2023-10-12 Astrazeneca Ab Polythérapie pour le traitement du cancer
WO2024203348A1 (fr) * 2023-03-31 2024-10-03 ソニーグループ株式会社 Procédé d'analyse de tumeurs, système d'analyse de tumeurs et procédé de génération de données d'analyse de tumeurs
CN121443291A (zh) * 2023-08-02 2026-01-30 詹森药业有限公司 尼拉帕尼和阿比特龙组合用于治疗转移性去势抵抗性前列腺癌

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3804730A1 (fr) * 2006-08-25 2021-04-14 Janssen Oncology, Inc. Compositions de traitement du cancer
US20080051380A1 (en) * 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
AR064777A1 (es) 2007-01-10 2009-04-22 Inst Di Reserche D Biolog Mole Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
JP5989965B2 (ja) 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
WO2012009475A1 (fr) * 2010-07-14 2012-01-19 Oregon Health & Science University Méthodes de traitement du cancer par inhibition de la déméthylase 1 spécifique de la lysine
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2014089324A1 (fr) * 2012-12-07 2014-06-12 Calitor Sciences, Llc Composés cycliques substitués et leurs procédés d'utilisation

Also Published As

Publication number Publication date
US20240245710A1 (en) 2024-07-25
SMT202200467T1 (it) 2023-01-13
EP3609497B1 (fr) 2022-10-12
MD3609497T2 (ro) 2023-03-31
EA201992430A1 (ru) 2020-02-28
PE20200444A1 (es) 2020-02-28
JOP20190244B1 (ar) 2024-04-18
EP3609497A1 (fr) 2020-02-19
HRP20221327T1 (hr) 2023-03-17
HUE060460T2 (hu) 2023-03-28
IL320452A (en) 2025-06-01
EP4176879A1 (fr) 2023-05-10
UA129514C2 (uk) 2025-05-21
IL269879A (fr) 2019-11-28
CA3059562A1 (fr) 2018-10-18
PL3609497T3 (pl) 2023-01-23
CR20190467A (es) 2020-03-09
JP2020516646A (ja) 2020-06-11
US20220175801A1 (en) 2022-06-09
MX2019012296A (es) 2019-11-28
MA48728A (fr) 2020-04-08
DOP2019000264A (es) 2020-07-15
CO2019011591A2 (es) 2020-02-28
AU2024202346A1 (en) 2024-05-02
NI201900105A (es) 2020-03-11
JP7407880B2 (ja) 2024-01-04
ES2931052T3 (es) 2022-12-23
LT3609497T (lt) 2022-12-12
IL269879B1 (en) 2025-06-01
EP4176878A1 (fr) 2023-05-10
JOP20190244A1 (ar) 2019-10-13
MY209010A (en) 2025-06-16
AU2024202346B2 (en) 2026-01-22
CN110753545A (zh) 2020-02-04
KR20190134718A (ko) 2019-12-04
US20180296574A1 (en) 2018-10-18
MX2023009569A (es) 2023-08-22
BR112019021466A2 (pt) 2020-05-12
JP2022141881A (ja) 2022-09-29
DK3609497T3 (da) 2022-10-31
JP2024023344A (ja) 2024-02-21
JP7141408B2 (ja) 2022-09-22
WO2018191141A1 (fr) 2018-10-18
AU2018251594A1 (en) 2019-10-24
CN119235874A (zh) 2025-01-03
PH12019502317A1 (en) 2020-07-06
PT3609497T (pt) 2023-01-23
MA48728B1 (fr) 2022-10-31
RS63832B1 (sr) 2023-01-31
CL2019002871A1 (es) 2019-12-27
JOP20230159A1 (ar) 2023-07-13
US20240398837A1 (en) 2024-12-05
IL269879B2 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
SG11201909552VA (en) Combination therapy for prostate cancer
SG11201909325RA (en) 2-amino-quinoline derivatives
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201900344YA (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201901715UA (en) Adenovirus armed with bispecific t cell engager (bite)
SG11201906543RA (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201901126UA (en) Combination therapy for cancer
SG11201811559WA (en) Cancer treatment combinations
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201809751XA (en) Egfr inhibitor compounds
SG11201808125RA (en) Methods for solid tumor treatment
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201407340YA (en) Treatment of myelosuppression
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201907693VA (en) Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof